Blog
RSS FeedPosted by Michael Wonder on 20 Aug 2022
Regulatory considerations to keep pace with innovation in digital health products
19 August 2022 - Rapid innovation and proliferation of software as a medical device have accelerated the clinical use of digital ...
Posted by Michael Wonder on 08 Aug 2022
Lurbinectedin receives the Innovative Medicine designation by the UK’s MHRA
5 August 2022 - PharmaMar has announced today that Zepzelca (lurbinectedin) has received the Innovation Passport (Innovative Medicine designation) by the ...
Posted by Michael Wonder on 02 Aug 2022
Critics decry drug pricing provisions in Inflation Reduction Act, say they will stifle innovation
2 August 2022 - The push back against the prescription drug pricing provisions in the Inflation Reduction Act is relentless and ...
Posted by Michael Wonder on 17 Jul 2022
'Government excessively controls drug prices, not recognising novel drugs' value'
15 July 2022 - The Government is wielding excessive power to lower drug prices without recognising the values of innovative ...
Posted by Michael Wonder on 14 Jul 2022
Revolo Biotherapeutics awarded Innovation Passport for ‘1805 in the United Kingdom for the treatment of moderate to severe rheumatoid arthritis
14 July 2022 - Revolo Biotherapeutics today announced that it was awarded an Innovative Medicines Designation, or Innovation Passport, from the ...
Posted by Michael Wonder on 28 Jun 2022
The Innovative Medicines Fund - good news for patients but has an opportunity been missed to be more ambitious?
27 June 2022 - NHS England and Improvement has announced the launch of the Innovative Medicines Fund. The ABPI’s Director ...
Posted by Michael Wonder on 16 Jun 2022
Savara awarded innovation passport in United Kingdom for molgramostim nebuliser solution, a novel investigational inhaled biologic
16 June 2022 - Innovation passport awarded to molgramostim for the treatment of auto-immune pulmonary alveolar proteinosis, a rare lung disease. ...
Posted by Michael Wonder on 15 Jun 2022
Shionogi signs agreement with NHS England to begin an innovative subscription payment model for reimbursement of its antibiotic, Fetcroja (cefiderocol)
15 June 2022 - Shionogi recognises the UK’s leadership role in introducing the world’s first fully ‘delinked’ pilot reimbursement model; pull ...
Posted by Michael Wonder on 15 Jun 2022
England’s Innovative Medicines Fund hits another milestone
15 June 2022 - Just like the Cancer Drugs Fund, the time-limited fund for the most promising cancer drugs introduced ...
Posted by Michael Wonder on 07 Jun 2022
Trends in prescription drug launch prices (2008-2021)
7 June 2022 - Prescription drug spending in the US exceeded half a trillion dollars in 2020. ...
Posted by Michael Wonder on 09 May 2022
The Center for Medicare and Medicaid Innovation - toward value based care
9 May 2022 - Before the enactment of the Patient Protection and Affordable Care Act in 2010, experimentation with Medicare or ...
Posted by Michael Wonder on 08 May 2022
Supporting innovation in Medicaid policy - interventions to increase adoption of RCTs
7 May 2022 - Randomised, controlled trials remain underutilised within the Medicaid program, even though state Medicaid programs regularly implement new ...
Posted by Michael Wonder on 21 Apr 2022
Are high cost prescription drugs the price of innovation? Disclose the costs of clinical trials.
21 April 2022 - With 40% of Americans struggling to afford prescription medicines and many rationing or delaying initiation of lifesaving ...
Posted by Michael Wonder on 29 Mar 2022
Nurix Therapeutics awarded Innovation Passport for entry into Innovative Licensing and Access Pathway in the United Kingdom for NX-1607
29 March 2022 - NX-1607 is being evaluated in multiple immuno-oncology indications, including a range of solid tumour types. ...
Posted by Michael Wonder on 03 Mar 2022
PRIME enables earlier availability of life-changing medicines
3 March 2022 - EMA’s PRIority Medicines (PRIME) scheme has had a positive impact on the authorisation of new medicines that ...